Adverse drug reactions (ADRs) are a common cause of attrition in drug discovery and
development and drug-induced liver injury (DILI) is a leading cause of preclinical and …

Adjuvant therapy is essential in cancer treatment to enhance primary treatment
effectiveness, reduce adverse effects, and prevent recurrence. Small molecule inhibitors as …

Background Immune checkpoint blockade (ICB) therapy has demonstrated considerable
clinical benefit in several malignancies, but has shown favorable response in only a small …

Targeting immune checkpoints such as programmed cell death protein 1 (PD-1) and
programmed death ligand-1 (PD-L1) have been approved for treating melanoma, gastric …

T-cell immunoglobulin and mucin domain 3 (TIM-3) is a negative immune checkpoint that
represents a promising target for cancer immunotherapy. Although encouraging results have …

Engineering polymeric nanoparticles for their shape, size, surface chemistry, and
functionalization using various targeting molecules has shown improved biomedical …

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related
deaths in the world. More than half of patients with HCC present with advanced stage, and …

Immune Checkpoint Inhibitors (ICIs) have remarkably modified the way solid tumors are
managed, including breast cancer. Unfortunately, only a relatively small number of breast …

T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3; HAVCR2) has
emerged as an attractive immune checkpoint target for cancer immunotherapy. TIM-3 is a …

ABSTRACT Epithelial–Mesenchymal Transition (EMT) is a fundamental biological process
involved in embryonic development, wound healing, and cancer progression. In lung …